| 6.68 -0.958 (-12.54%) | 11-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.54 |
1-year : | 11.15 |
| Resists | First : | 8.17 |
Second : | 9.54 |
| Pivot price | 0.79 |
|||
| Supports | First : | 3.27 |
Second : | 0.25 |
| MAs | MA(5) : | 1.68 |
MA(20) : | 0.68 |
| MA(100) : | 0.56 |
MA(250) : | 0.69 |
|
| MACD | MACD : | 0.5 |
Signal : | 0 |
| %K %D | K(14,3) : | 82.3 |
D(3) : | 80.5 |
| RSI | RSI(14): 98.8 |
|||
| 52-week | High : | 8.17 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PMCB ] has closed above the upper band by 43.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 3572.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.18 - 8.21 | 8.21 - 8.25 |
| Low: | 6.43 - 6.46 | 6.46 - 6.49 |
| Close: | 6.78 - 6.82 | 6.82 - 6.88 |
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.
Sat, 14 Nov 2026
PharmaCyte Biotech Stock (PMCB) - Quote Nasdaq - www.marketscreener.com
Fri, 13 Nov 2026
PMCB: PharmaCyte Biotech Inc. filed SEC Form 8-K: Material... - Quantisnow
Fri, 13 Nov 2026
PharmaCyte Biotech Reports Strong Cash and Asset Position - Investing News Network
Thu, 12 Nov 2026
PharmaCyte Biotech, Inc. Announces Reverse Stock Split - Investing News Network
Fri, 30 Oct 2026
PharmaCyte Biotech, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (PMCB) - Traders Union
Fri, 30 Oct 2026
PharmaCyte Biotech, Inc. (PMCB) Stock Price Prediction for 2026, 2030-2040 - Traders Union
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 5.7 (%) |
| Held by Institutions | 7.2 (%) |
| Shares Short | 70 (K) |
| Shares Short P.Month | 70 (K) |
| EPS | -2.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -8.4 % |
| Return on Equity (ttm) | -44 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -2.96 |
| PEG Ratio | 0 |
| Price to Book value | 2.62 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|